Association between statin use and major adverse cardiovascular events in patients with chronic kidney disease and cardiomyopathy: A retrospective case-control study - PubMed
4 hours ago
- #chronic kidney disease
- #cardiomyopathy
- #statin
- Study investigates statin use and major adverse cardiovascular events (MACE) in CKD patients with cardiomyopathy.
- 765 patients included (255 cases, 510 controls); statin use prevalence was 59.6%, lower in cases (48.2%) vs. controls (65.3%).
- Statin use associated with reduced MACE risk (unadjusted OR = 0.52, 95% CI: 0.38-0.70, P < .001).
- Dose-response analysis shows MACE incidence decreases with higher statin doses (41.1% nonusers, 28.7% low-moderate, 20.2% high-dose, P for trend = .002).
- Multivariable analysis confirms statin therapy independently lowers MACE risk, strongest in high-dose group (adjusted OR = 0.47, 95% CI: 0.31-0.72, P = .001).
- Protective effects consistent across CKD stages and cardiomyopathy types (ischemic vs. non-ischemic; P for interaction > .05).
- Statin therapy well-tolerated, with only mild, reversible side effects (elevated liver/muscle enzymes).